Mirte Balke-Buijs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mirte Balke-Buijs has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anastasia Tsakmaklis
Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
1 shared publication Angela Talley
Spero Therapeutics, Cambridge, MA, USA
1 shared publication- Annefleur D. O. Hensen
Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
1 shared publication B Kim Lee Sim
Sanaria, Rockville, MD, USA
1 shared publication- C. Crul
Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
1 shared publication - Caroline J. Duncombe
Graduate Program in Pathobiology, Department of Global Health, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial
Clostridioides difficile infections remain a major global healthcare burden, underscoring the need for novel therapies. Human colonisation models provide mechanistic insight into C. difficile colonisation and facilitate identification of novel intervention targets. We conducted a placebo-controlled, randomised clinical trial (NCT05693077) administering non-toxigenic C. difficile (NTCD) capsules to healthy participants to assess safety and colonisation as primary endpoints, and microbiota susceptibility as a secondary endpoint. A total of 69 healthy participants (18-45 years), not previously colonised with C. difficile and without recent antibiotic use, were enrolled following a health assessment. NTCD capsules administered for five consecutive days at low or high dose, was safe with no dose-response relationship in colonisation outcomes. Vancomycin pretreatment induced colonisation success: with 5% colonisation without, 32% after one day, and 84% after five days vancomycin pretreatment. Some participants that cleared vancomycin rapidly acquired non-challenge C. difficile strains prior to NTCD challenge. Microbiota profiling (using shotgun metagenomics) revealed reduced α-diversity and pronounced community restructuring. These findings highlight the impact of antibiotic-mediated microbiota disruption, the widespread environmental presence of C. difficile, and the feasibility of meaningful microbiota assessment in small-scale intervention trials, thereby providing a robust tool to investigate this globally impactful infection.
- 12 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessExperimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial
Clostridioides difficile infections remain a major global healthcare burden, underscoring the need for novel therapies. Human colonisation models provide mechanistic insight into C. difficile colonisation and facilitate identification of novel intervention targets. We conducted a placebo-controlled, randomised clinical trial (NCT05693077) administering non-toxigenic C. difficile (NTCD) capsules to healthy participants to assess safety and colonisation as primary endpoints, and microbiota susceptibility as a secondary endpoint. A total of 69 healthy participants (18-45 years), not previously colonised with C. difficile and without recent antibiotic use, were enrolled following a health assessment. NTCD capsules administered for five consecutive days at low or high dose, was safe with no dose-response relationship in colonisation outcomes. Vancomycin pretreatment induced colonisation success: with 5% colonisation without, 32% after one day, and 84% after five days vancomycin pretreatment. Some participants that cleared vancomycin rapidly acquired non-challenge C. difficile strains prior to NTCD challenge. Microbiota profiling (using shotgun metagenomics) revealed reduced α-diversity and pronounced community restructuring. These findings highlight the impact of antibiotic-mediated microbiota disruption, the widespread environmental presence of C. difficile, and the feasibility of meaningful microbiota assessment in small-scale intervention trials, thereby providing a robust tool to investigate this globally impactful infection.
- Open Access
- 13 January 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (2) , 101265
Sex-based differences in Plasmodium infection in the control groups of controlled human malaria infection trials in malaria-naive populations in the USA and the Netherlands: a pooled analysis
- 13 January 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (2) , 101265
Open AccessSex-based differences in Plasmodium infection in the control groups of controlled human malaria infection trials in malaria-naive populations in the USA and the Netherlands: a pooled analysis